Kancera’s presentation at the Redeye Technology & Life Science Day 2024
Kancera presentation at the Redeye Theme: Cardiovascular & Metabolic Diseases Event 2024
Presentation of Kancera’s Interim Report for the first quarter 2024
Presentation of Kancera’s Interim Report for the fourth quarter 2023
Presentation of the statistical analyses of the FRACTAL top line results
CEO Peter Selin presents Kancera’s Q3 2023 Interim Report
CEO Peter Selin presents KANDOVA, Kancera’s ongoing clinical study in ovarian cancer